Duel-acting subcutaneous microemulsion formulation for improved migraine treatment with zolmitriptan and diclofenac: Formulation and in vitro-in vivo characterization

AAPS Journal

Volumn 16, Issue 2, 2014, Pages 214-220

  Dubey, R ^a,b   Martini, Luigi G ^a,c,d   Christie, Mark ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b DR REDDY'S LABORATORIES LTD   (India)

^c Pharmaceutical Innovation   (United States)

^d Rainbow Medical Engineering Ltd   (United Kingdom)

Author keywords

diclofenac acid; dual acting injection; migraine treatment; prolonged release microemulsion; subcutaneous injection; zolmitriptan

Indexed keywords

CAPRYLIC CAPRIC TRIGLYCERIDE; CAPRYOL 90; DICLOFENAC; EMULSIFYING AGENT; OIL; POLYSORBATE 80; UNCLASSIFIED DRUG; WATER; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MIGRAINE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SUSTAINED DRUG RELEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; EMULSIONS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIGRAINE DISORDERS; OXAZOLIDINONES; RATS; RATS, WISTAR; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TRYPTAMINES;

EID: 84895867506     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9557-4     Document Type: Article

References (26)

1. Purdue Pharma L.P. General pain: fact sheet. 2013. http://www. inthefaceofpain.com/content/uploads/2011/12/factsheet--Pain.pdf Accessed 10 Sep 2013.
2. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012;15 Suppl 1:S15-22.
3. Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol. 2010;9:309-17.
4. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009;16(Eversa S):968-81.
5. Smith TR, Sunshine A, Stark SR, et al . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983-91.
6. Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Can J Neurol Sci. 2001;28:30-41.
7. Gillian C. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62:563-8.
8. Schoenen J, Pascual J, Rasmussen S, et al. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur J Neurol. 2005;12:108-17. (Pubitemid 40260729)
9. Kikuchi H, Carlsson A, Yachi K, et al. Possibility of heat sterilization of liposomes. Chem Pharm Bull. 1991;39:1018-22.
10. Burgess DJ, Hussain AS, Ingallinera TS, et al. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS Pharm Sci. 2002;4:13-23.
11. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89-121.
12. Karasulu HY. Microemulsions as novel drug carriers: the formation, stability, applications and toxicity. Expert Opin Drug Deliv. 2008;5:119-35. (Pubitemid 351234113)
13. Koga K, Nishimon Y, Ueta H, et al. Utility of nano-sized, water-in-oil emulsion as a sustained release formulation of glycyrrhizin. Biol Pharm Bull. 2011;34:300-5.
14. Constantinides PP, Lambert KJ, Tustian AK, et al. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res. 2000;17:175-82. (Pubitemid 30158366)
15. Borhade VB, Nair HA, Hegde DD. Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration. Drug Dev Ind Pharm. 2009;35:619-30.
16. Djordjevic L, Primorac M, Stupar M, et al. Characterization of caprylocaproyl macrogoglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. Int J Pharm. 2004;271:11-9. (Pubitemid 38210080)
17. Djordjevic L, Primorac M, Stupar M. In vitro release of diclofenac diethylamine from caprylocaproyl macrogolglycerides based microemulsions. Int J Pharm. 2005;296:73-9. (Pubitemid 40693374)
18. Ke WT, Lin SY, Ho H-O, et al. Physical characterization of microemulsion systems using tocopheryl polyethylene glycol 1000 succinate (TPGS) as a surfactant for the oral delivery of protein drugs. J Control Release. 2005;102:489-507. (Pubitemid 40093768)
19. Washington C, Evans K. Release rate measurements of model hydrophobic solutes from submicron triglyceride emulsion. J Control Release. 1995;33:383-90.
20. Prince LM. Emulsion and emulsion technology, part I. New York: Marcel Dekker; 1974.
21. Fini A, Fazio G, Rapaport I. Diclofenac/N-(2-hydroxyethyl)pyrrolidine: a new salt for an old drug. Drugs Exp Clin Res. 1993;XIX:81-8. (Pubitemid 24000673)
22. Liu J, Zhou X. Determination of zolmitriptan and its primary metabolite, n-desmethy-zolmitriptan, in rat plasma by LC-MSMS. J Chromatogr Sci. 2013;51:59-64.
23. Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, Aristorena JC, Pla-Delfina JM. Pharmacokinetics and bioavailability of diclofenac in the rat. J Pharmacokinet Biopharm. 1991;19:647-65.
24. D'Souza SS, DeLuca PP. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res. 2006;23:460-74.
25. Etherton TD, Bauman DE, Romans JR. Lipolysis in subcutaneous and perirenal adipose tissue from sheep and dairy steers. J Anim Sci. 1977;44:1100-6.
26. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham M, Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol. 1994;257:249-55. (Pubitemid 24154581)